Medios announces share buyback program of up to €19 million over one year
Key Facts
Medios announced on November 18, 2026, a share buyback program worth up to €19 million, with execution set to begin the following day and end no later than November 19, 2027. The program targets the purchase of up to 1,500,000 shares, equivalent to around 5.88% of registered capital of €25,505,723. The company said the financial cap excludes incidental purchase costs. The reported 8% rise in the share price during the November 19 session could not be verified from a reliable open source, so no specific price move can be attributed to the announcement. The decision is part of a share buyback plan announced by the company, rather than evidence in itself of the stock’s trading direction.
Chief Executive Thomas Meyer said the program implements the capital allocation strategy the company presented at its Capital Markets Day in late September 2026. He added that the move reflects management’s confidence in the business model, financial strength and potential for sustainable growth. These statements explain the rationale for the decision as presented by management, without establishing investors’ reaction or explaining the share-price move. Execution is based on authorization granted at the annual general meeting held on June 10, 2026. The authorization allows the company to repurchase shares amounting to up to 10% of capital until June 9, 2031, subject to the terms set out in it.
The new program comes as Medios holds 986,362 treasury shares from a previous buyback, equivalent to around 3.87% of capital at the time of the November 18, 2026 announcement. The company said it intends to cancel those shares soon and reduce capital accordingly. These retained shares differ from the amount targeted by the new plan: the company says the previous shares will be canceled, while the current authorization permits share repurchases within its limits and terms. In a public tender offer in 2025, the company bought shares representing around 3.92% of issued capital. That transaction was settled on July 17, 2025.
The announcement follows results for the first nine months of 2026, which showed consolidated revenue rising 6.7% to €1,633.0 million. In the same period, EBITDA before special items was €66.7 million, compared with €70.4 million in the corresponding period of 2025, while the margin fell to 4.1% from 4.6%. Operating cash flow was also €26.2 million, down 50.2% from €52.7 million in the first nine months of 2025. The company attributed the decline mainly to higher tax payments and lower earnings, alongside factors related to the timing of payments and receipts in the previous year. Meyer said the EBITDA margin before special items in the Patient-Specific Therapies segment improved quarter on quarter for the third consecutive time through the third quarter of 2026.
The company reaffirmed its 2026 financial-year guidance, excluding mergers and acquisitions, of consolidated revenue between €2.10 billion and €2.16 billion and EBITDA before special items between €88 million and €92 million. It said the expected figure for EBITDA before special items is likely to come in at the lower end of the range. The company also expects an amendment to the German Hilfstaxe agreement to add a burden of around €1.2 million to the indicator in the Patient-Specific Therapies segment during the fourth quarter of 2026. Over a longer horizon, the “Medios Next Level” strategy targets group revenue of around €3.1 billion and an adjusted EBITDA margin of around 5.5% for the 2031 financial year. The company’s upcoming events include the Frankfurt Equity Forum from November 23 to 25, 2026, and the Berenberg European Conference on December 3, 2026.